Subject(s)
COVID-19 , Drug Hypersensitivity , Skin Diseases , Antiviral Agents , Drug Hypersensitivity/diagnosis , Humans , SARS-CoV-2Subject(s)
COVID-19 Vaccines , COVID-19 , Arm , BNT162 Vaccine , Health Personnel , Humans , RNA, Messenger , SARS-CoV-2Subject(s)
COVID-19 , Chilblains , Case-Control Studies , Chilblains/diagnosis , Humans , SARS-CoV-2 , SkinSubject(s)
COVID-19/complications , Skin Diseases/virology , Adult , Biomarkers/blood , COVID-19/epidemiology , Female , Humans , Male , Middle Aged , Pandemics , SARS-CoV-2 , Skin Diseases/epidemiologySubject(s)
Coronavirus Infections/epidemiology , Pandemics/statistics & numerical data , Pneumonia, Viral/epidemiology , Urticaria/pathology , Vasculitis, Leukocytoclastic, Cutaneous/epidemiology , Vasculitis, Leukocytoclastic, Cutaneous/pathology , Aged , Biopsy, Needle , COVID-19 , Comorbidity , Coronavirus Infections/diagnosis , Female , Humans , Immunohistochemistry , Incidence , Male , Middle Aged , Pneumonia, Viral/diagnosis , Prognosis , Risk Assessment , Sampling Studies , Severity of Illness Index , Urticaria/diagnosis , Urticaria/epidemiologyABSTRACT
COVID-19 is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2). Vesicular skin rashes have been reported as associated with COVID-19, but there is little information about this cutaneous manifestation. We designed a prospective observational study of patients diagnosed with COVID-19 who had vesicular lesions. Clinical characterization of skin findings was conducted by dermatologists. When possible, histological analysis and detection of SARS-CoV-2 in the content of the vesicles was performed. In total, 24 patients were included. A disseminated pattern was found in 18 patients (75%), and a localized pattern was found in 6 (25%). Median duration of the skin rash was 10 days. Of the 24 patients, 19 (79.2%) developed the skin rash after the onset of COVID-19 symptoms. Histological examination in two patients was consistent with viral infection, SARS-CoV-2 was not detected in four patients. This single-centre study shows the clinical characteristics of vesicular skin rashes in patients with COVID-19.